Table 4.

Baseline characteristics of the cyclosporine and tacrolimus subgroups

VariableTacrolimus (n = 197)Cyclosporine (n = 273)Probability
Age46 ± 1251 ± 13<0.001
Male gender % (n)53.8 (106)62.6 (171)0.055
Deceased donor (%)66.5 (131)66.7 (182)0.969
Duration transplant2.6 ± 2.66.9 ± 5.0<0.001
Any cardiovascular disease22.8 (45)30.8 (84)0.058
Diabetes mellitus pretreatment25.4 (50)17.6 (48)0.04
New-onset diabetes mellitus19.3 (38)16.1 (44)0.372
EKG left ventricular hypertrophy13.3 (26/195)22.7 (58/256)0.012
Body mass index28.4 ± 6.130.0 ± 6.60.363
Smoking23.9 (47)17.9 (48)0.116
Systolic BP131 ± 17135 ± 170.043
Diastolic BP78 ± 978 ± 100.517
Total cholesterol4.83 ± 1.025.40 ± 1.15<0.001
LDL2.69 ± 0.812.93 ± 0.93<0.001
Albumin38 ± 438 ± 40.419
Hemoglobin132 ± 17129 ± 160.041
Creatinine clearance67 ± 2557 ± 21<0.001
Dipstick >negative27.7 (54)31.0 (83)0.447
ASA29.4 (58)33.7 (92)0.33
β-blocker50.5 (99)49.8 (136)0.926
ACEi/ARB36.0 (71)48.7 (133)0.006
Statin42.1 (83)58.2 (159)0.001